Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2018 16:52 ET | Source: Myriad Genetics, Inc.

Myriad Announces Publication of IMPACT Study in Journal of Psychiatric Research

SALT LAKE CITY, July 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that results from the Individualized Medicine:...
July 18, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces Coverage Decision by Kroger® Prescription Plans for Vectra DA®

SALT LAKE CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide...
June 28, 2018 07:05 ET | Source: Myriad Genetics, Inc.

BRACAnalysis® CDx Identifies Patients Who Respond to Lynparza® in SOLO-1 Study

SALT LAKE CITY, June 28, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that the Company’s BRACAnalysis® CDx test...
June 21, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Top-Five National Payer Issues Positive Coverage Decision for Myriad’s Prolaris® Test for Prostate Cancer

SALT LAKE CITY, June 21, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has received a positive...
June 18, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer

SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug...
June 06, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Featured at the 2018 European League Against Rheumatism Annual Meeting

SALT LAKE CITY, June 06, 2018 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that data on the use of the Vectra® DA test...
June 01, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

SALT LAKE CITY, June 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from a second major...
May 31, 2018 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at Two Upcoming Investor Conferences

SALT LAKE CITY, May 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two...
May 31, 2018 07:05 ET | Source: Myriad Genetics, Inc.

GeneSight® Guided Treatment Significantly Improves Outcomes for Patients with Major Depression Treated in the Primary Care Setting

New Results from the IMPACT Study to be Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting SALT LAKE CITY, May 31, 2018 (GLOBE NEWSWIRE) -- Assurex Health, a...
May 28, 2018 18:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Signs Definitive Agreement to Acquire Counsyl, Inc.

SALT LAKE CITY, May 28, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive...